Search

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Speak Up

The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Collaboration key to meeting consumers’ expectations for better animal welfare

Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care

BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

ABILD02

The ABILD02 partnership aims to understand ILD patients needing oxygen therapy, identifying facilitators and barriers to its use via stakeholder consultations.

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Code of Conduct

Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.

Boehringer Ingelheim increases commitments to sustainable development

Helping patients by addressing health system gaps

AHEAD Program

The partnership program led by Boehringer Ingelheim Canada to address gaps in Canada’s health system for people living with T2D and heart failure. Click to read more.

Machine learning for patients

Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.

COACH Program

The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Social media community guidelines

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Speak Up

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Collaboration key to meeting consumers’ expectations for better animal welfare

Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

Alberta’s Dr. Karin Orsel named 2020 Metacam® 20 Bovine Welfare Award winner

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

ABILD02

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Code of Conduct

Boehringer Ingelheim increases commitments to sustainable development

Helping patients by addressing health system gaps

Helping patients by addressing health system gaps

AHEAD Program

Machine learning for patients

COACH Program

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Social media community guidelines

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones